newsfilter
← Latest News
GlobeNewswire·

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that